Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)

Market Cap	3.85B
Revenue (ttm)	454.44M
Net Income (ttm)	66.87M
Shares Out	108.29M
EPS (ttm)	0.62
PE Ratio	57.17
Forward PE	n/a
Dividend	0.20 (0.56%)
Ex-Dividend Date	May 20, 2025

Volume	4,388,916
Average Volume	3,431,641
Open	36.87
Previous Close	36.96
Day's Range	36.61 - 37.82
52-Week Range	18.52 - 58.66
Beta	-1.75
RSI	46.21
Earnings Date	Aug 16, 2025

About SHE:301281

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of active pharmaceutical ingredients. It offers gliclazide, for the treatment of NIDDM; metformin hydrochloride used as an adjunct to diet and exercise in adult patients with NIDDM; isosorbide mononitrate for prevention of angina pectoris and treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction; isosorbide dinitrate to prevent angina pectoris due to coronary artery disease; mecobalamin for periphera...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2004
• Employees: 696
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301281

Financial Performance

In 2024, SHE:301281's revenue was 463.72 million, an increase of 3.60% compared to the previous year's 447.58 million. Earnings were 60.27 million, a decrease of -21.76%.